Dominic allowed me to publish a series of articles he had written called “Psychedelic Skeletons in the Closet” that focused ...

Up the Junction Mushrooms can be a scary food. Whether it’s the texture, the taste, the fact they can be poisonous, or even ...

The FDA announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. It's a significant step toward supporting psychedelic-based medicines ...

A PSYCHEDELICS ‘BREAKTHROUGH’? The list of products receiving FDA Commissioner Marty Makary’s priority review vouchers will grow this week to include three psychedelic drugs after a White House ...

Trump's order on psychedelics sent stocks in the space soaring on Monday. Trump signed an executive order to loosen restrictions in order to hasten the development for medical use. The news boosted ...

April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews ‌of psychedelic ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Shares of biotech firms and companies providing psychedelic-assisted therapy surged on ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Trump signed an executive order Saturday to ease research restrictions on psychedelic drugs like psilocybin and LSD, aiming to accelerate studies into their potential for treating mental health ...

Producer Norman Whitfield was a man of few words. But his musical work and legacy continue to speak volumes. That’s one of the big takeaways while absorbing “Psychedelic Soul: A Journey Through Rhythm ...

Madonna is returning to the dance floor. The pop icon has revealed that her new album, "Confessions on a Dance Floor II" will release on July 3.

Deutsche Bank believes AtaiBeckley is well-positioned to be a winner in the "Psychedelic Renaissance." The bank initiated coverage on the drug developer with a buy rating and a $12 price target, which ...